Drugs / biphasic human insulin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01697618 | Apr 1997 → Nov 1998 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT00476437 | Apr → Nov 2007 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 3 | NCT00617565 | Jul → Nov 2003 | type 1 diabetes mellitus, type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00698802 Comparator | Jun 2008 → Mar 2009 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01467401 Comparator | Aug 2002 → May 2003 | type 2 diabetes mellitus | Novo Nordisk A/S | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | biphasic human insulin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01697618 ↗ |
| Known as | Mixtard 30 | “The aim of this trial is to investigate the efficacy and safety of biphasic insulin aspart (NovoMix®30) to that of biphasic human insulin (Mixtard® 30) in subjects with type 2 diabetes.” NCT01467401 ↗ |
| Modality | Protein / enzyme biologic | “equivalent premixed biphasic human insulin (BHI 30)” PMID 12017398 ↗ Apr 2002 |
| Route | Subcutaneous | “Injected subcutaneously (s.c., under the skin) before breakfast and dinner” NCT01697618 ↗ |